Storia in 2 fonti

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

The recent rally in the stock followed the USFDA’s approval for Zaynich (cefepime and zidebactam), an intravenous antibiotic for treating adults with complicated urinary tract infections (cUTI)

Raccontata da

economictimes.indiatimes.com

thehindubusinessline.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

thehindubusinessline.comStai leggendo3 mesi fa

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt gained FDA approval for Zaynich (novel antibiotic for UTIs); stock surged 36.77% then fell 9% on profit-taking. Independent global distribution by Wockhardt marks India's first self-developed breakthrough drug without pharma partnerships.

originale

economictimes.indiatimes.com3 mesi fa

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?

Wockhardt shares dropped after a recent surge, as investors took profits. This followed the US FDA approval of ZAYNICH, an antibiotic for urinary tract infections. The company also reported a strong turnaround in its…

Timeline cronologica

lunedì 1 giugno 2026·economictimes.indiatimes.com
Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt will be in focus after the US FDA approved ZAYNICH, a novel intravenous antibiotic combining cefepime and zidebactam for complicated urinary tract infections. The drug…
martedì 2 giugno 2026·economictimes.indiatimes.com
Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting…

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?

Timeline cronologica

Wockhardt shares in focus after FDA approval for antibiotic targeting drug-resistant infections. Check details

Zaynich's blockbuster potential lifts Wockhardt's long-term outlook

Wockhardt shares tumble 9% amid profit booking after sharp rally on Zaynich approval

Wockhardt shares pause massive 36% rally in 5 sessions; slip 7%. What’s behind the selloff?